Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?

Detalhes bibliográficos
Autor(a) principal: Antas, Paulo R. Z
Data de Publicação: 2013
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/10534
Resumo: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.
id CRUZ_d19857f316a642efc98e471a34c886d2
oai_identifier_str oai:www.arca.fiocruz.br:icict/10534
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Antas, Paulo R. Z2015-05-27T13:39:47Z2015-05-27T13:39:47Z2013ANTAS, Paulo R.Z. Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?. J. Anc Dis Prev Rem, v.2, n.1, 3p, 2013.2329-8731https://www.arca.fiocruz.br/handle/icict/1053410.4172/2329-8731.1000108engOmics InternationalTuberculoseTuberculosisBCG VaccinesVacina BCGTuberculoseNovel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.Bacillus Calmette-Guerin (BCG) is the common name given to a family of vaccines against human tuberculosis. Created in 1921 by the in vitro attenuation of a virulent Mycobacterium bovis in France, the BCG vaccine continues to generate debate and confusion after nearly a century of use. Since the 1940s, significant sequence differences among the BCG strains have been reported. In addition, relationships between the recombinant BCG vaccines used in current clinical trials and their parental strains have been never fully delineated. In order to standardize and to clarify the subject regarding common BCG strains used to generate those novel vaccines, a sequential emergence of the parental strains and their matching recombinant strains was built. Hence, for a total of 16 BCG strains in worldwide circulation, 9 have been used to sustain one or more genetic alterations, resulting in around 21 novel recombinant BCG strains. Although it is an outstanding achievement, only 2 out of the 21 recombinant strains are from the most immunogenic group. Systematizing the novel BCG vaccines and their parental strains may facilitate our understanding of protection provided by BCG immunizations.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1914https://www.arca.fiocruz.br/bitstream/icict/10534/1/license.txt7d48279ffeed55da8dfe2f8e81f3b81fMD51ORIGINALpaulo_antas_IOC_2014.pdfapplication/pdf814321https://www.arca.fiocruz.br/bitstream/icict/10534/2/paulo_antas_IOC_2014.pdffe1391f2ce99a5842dfb4f169069cc18MD52TEXTpaulo_antas_IOC_2014.pdf.txtpaulo_antas_IOC_2014.pdf.txtExtracted texttext/plain13374https://www.arca.fiocruz.br/bitstream/icict/10534/3/paulo_antas_IOC_2014.pdf.txt0041543104db1d0d8b04898738cbd134MD53icict/105342022-06-24 12:17:34.706oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-06-24T15:17:34Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
title Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
spellingShingle Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
Antas, Paulo R. Z
Tuberculose
Tuberculosis
BCG Vaccines
Vacina BCG
Tuberculose
title_short Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
title_full Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
title_fullStr Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
title_full_unstemmed Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
title_sort Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?
author Antas, Paulo R. Z
author_facet Antas, Paulo R. Z
author_role author
dc.contributor.author.fl_str_mv Antas, Paulo R. Z
dc.subject.other.pt_BR.fl_str_mv Tuberculose
topic Tuberculose
Tuberculosis
BCG Vaccines
Vacina BCG
Tuberculose
dc.subject.en.pt_BR.fl_str_mv Tuberculosis
BCG Vaccines
dc.subject.decs.pt_BR.fl_str_mv Vacina BCG
Tuberculose
description Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil.
publishDate 2013
dc.date.issued.fl_str_mv 2013
dc.date.accessioned.fl_str_mv 2015-05-27T13:39:47Z
dc.date.available.fl_str_mv 2015-05-27T13:39:47Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ANTAS, Paulo R.Z. Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?. J. Anc Dis Prev Rem, v.2, n.1, 3p, 2013.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/10534
dc.identifier.issn.pt_BR.fl_str_mv 2329-8731
dc.identifier.doi.pt_BR.fl_str_mv 10.4172/2329-8731.1000108
identifier_str_mv ANTAS, Paulo R.Z. Novel Recombinant BCG Vaccines: Do the Ordinary Platforms Matter?. J. Anc Dis Prev Rem, v.2, n.1, 3p, 2013.
2329-8731
10.4172/2329-8731.1000108
url https://www.arca.fiocruz.br/handle/icict/10534
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Omics International
publisher.none.fl_str_mv Omics International
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/10534/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/10534/2/paulo_antas_IOC_2014.pdf
https://www.arca.fiocruz.br/bitstream/icict/10534/3/paulo_antas_IOC_2014.pdf.txt
bitstream.checksum.fl_str_mv 7d48279ffeed55da8dfe2f8e81f3b81f
fe1391f2ce99a5842dfb4f169069cc18
0041543104db1d0d8b04898738cbd134
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009129207234560

Registros relacionados